Dr. Chunyan Gao, Harbin Medical University-Daqing, China
Dr. Chunyan Gao is a distinguished medical professional and researcher at Harbin Medical University-Daqing, China. She holds extensive expertise in her field, contributing to medical education and research with a focus on public health and medical sciences. Dr. Gao has published numerous scholarly articles and actively participates in both national and international research collaborations, reflecting her dedication to advancing medical knowledge and improving healthcare outcomes. Her work is particularly recognized for its impact on community health initiatives and academic excellence.
Education:
Dr. Chunyan Gao completed her Ph.D. at Harbin Medical University, China, from 2010 to 2013, following her M.S. degree from the same university between 2004 and 2007. She earned her B.S. from Jiamusi University, China, in 2001. Dr. Gao’s educational background reflects a strong foundation in medical sciences, contributing to her expertise and research endeavors in the field.
Dr. Chunyan Gao has had a distinguished academic career at Harbin Medical University-Daqing, where she has held several key positions since 2001. She began as a Teaching Assistant in the Department of Medical Laboratory Science and Technology from 2001 to 2006, then became a Lecturer from 2006 to 2011. Dr. Gao was promoted to Associate Professor from 2011 to 2015 and has served as a Professor in the same department since 2015. Additionally, she was a Visiting Scholar at the Blood Research Institute, Versiti Wisconsin, in Milwaukee, WI, from 2015 to 2018. Her extensive experience in education and research underscores her commitment to advancing the field of medical laboratory science.
Dr. Chunyan Gao, MD, PhD, is a leading researcher at Harbin Medical University-Daqing, China, focusing on thrombosis and hemostasis. Currently, she serves as the Principal Investigator for several high-profile projects, including a National Natural Science Foundation of China grant (Project No. 82270134, 2023-2026). Dr. Gao has successfully completed various significant projects, such as Project No. 82070140 (2021-2024) and Project No. 81400097 (2015-2017) under the same foundation. Her portfolio also includes the Marshal Initiative Funding (HMUMIF-22005, 2022-2023) and multiple other provincial and institutional grants, showcasing her substantial contributions to advancing research in her field.
In conclusion, Dr. Chunyan Gao’s extensive research in thrombosis and hemostasis has positioned her as a prominent figure in her field. Through her leadership as Principal Investigator on numerous prestigious projects, including those funded by the National Natural Science Foundation of China and various provincial initiatives, she continues to drive significant advancements in medical science. Her ongoing work not only enhances our understanding of critical health issues but also paves the way for innovative treatments and interventions, reflecting her commitment to improving patient outcomes in the area of vascular health.
Yan, M., Wang, Z., An, Y., … Wang, D., Gao, C. (2024). OxLDL enhances procoagulant activity of endothelial cells by TMEM16F-mediated phosphatidylserine exposure. Cell Biology International, 48(6), pp. 848–860.
Li, Z., Yan, M., Wang, Z., … Wang, L., Gao, C. (2022). Ferroptosis of Endothelial Cells Triggered by Erythrophagocytosis Contributes to Thrombogenesis in Uremia. Thrombosis and Haemostasis, 123(12), pp. 1116–1128.
Yan, M., Xu, M., Li, Z., … Shi, J., Gao, C. (2022). TMEM16F mediated phosphatidylserine exposure and microparticle release on erythrocyte contribute to hypercoagulable state in hyperuricemia. Blood Cells, Molecules, and Diseases, 96, 102666.
Yu, H., Wang, Z., Li, Z., … Shi, J., Gao, C. (2021). Hyperuricemia enhances procoagulant activity of vascular endothelial cells through TMEM16F regulated phosphatidylserine exposure and microparticle release. FASEB Journal, 35(9), e21808.
Chen, Y., Schroeder, J.A., Gao, C., … Hu, J., Shi, Q. (2021). In vivo enrichment of genetically manipulated platelets for murine hemophilia B gene therapy. Journal of Cellular Physiology, 236(1), pp. 354–365.
Ji, S., Dong, W., Qi, Y., … Shi, J., Gao, C. (2020). Phagocytosis by endothelial cells inhibits procoagulant activity of platelets of essential thrombocythemia in vitro. Journal of Thrombosis and Haemostasis, 18(1), pp. 222–233.
Gao, C., Schroeder, J.A., Xue, F., … Czechowicz, A., Shi, Q. (2019). Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice. Blood Advances, 3(18), pp. 2700–2711.
Ma, R., Xie, R., Yu, C., … Zhou, J., Shi, J. (2018). Erratum: Publisher Correction: Phosphatidylserine-mediated platelet clearance by endothelium decreases platelet aggregates and procoagulant activity in sepsis. Scientific Reports, 8(1), pp. 6224.
Ma, R., Xie, R., Yu, C., … Zhou, J., Shi, J. (2017). Phosphatidylserine-mediated platelet clearance by endothelium decreases platelet aggregates and procoagulant activity in sepsis. Scientific Reports, 7(1), 4978.
Gao, C., Xie, R., Yu, C., … Zhou, J., Shi, J. (2015). Thrombotic role of blood and endothelial cells in uremia through phosphatidylserine exposure and microparticle release. PLoS ONE, 10(11), e0142835.
